Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
20
01
2021
accepted:
09
04
2021
revised:
29
03
2021
pubmed:
13
5
2021
medline:
14
10
2021
entrez:
12
5
2021
Statut:
ppublish
Résumé
Temcell is a cryopreserved, human bone marrow-derived mesenchymal stem cell (MSC) product approved for the treatment of patients of all ages with acute graft-versus-host disease (GVHD). Initial experience with Temcell in a real-world setting from a cellular therapy registry in Japan is presented. A total of 381 consecutive patients were enrolled since its approval in 2016. The median cell number infused was 2.00 × 10
Identifiants
pubmed: 33976381
doi: 10.1038/s41409-021-01304-y
pii: 10.1038/s41409-021-01304-y
doi:
Substances chimiques
Steroids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2355-2366Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N. Engl J Med. 2017;377:2167–79.
pubmed: 29171820
pmcid: 6034180
doi: 10.1056/NEJMra1609337
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transpl. 2015;21:761–7.
doi: 10.1016/j.bbmt.2015.01.001
Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2013;19:1183–9.
doi: 10.1016/j.bbmt.2013.05.003
Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia .2020;34:1229–40.
pubmed: 32242050
pmcid: 7192843
doi: 10.1038/s41375-020-0804-2
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36.
pubmed: 19172693
doi: 10.1038/nri2395
Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet .2004;363:1439–41.
pubmed: 15121408
doi: 10.1016/S0140-6736(04)16104-7
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet .2008;371:1579–86.
pubmed: 18468541
doi: 10.1016/S0140-6736(08)60690-X
von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transpl. 2009;43:245–51.
doi: 10.1038/bmt.2008.316
Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transpl. 2011;17:534–41.
doi: 10.1016/j.bbmt.2010.04.014
Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013;163:501–9.
pubmed: 23992039
doi: 10.1111/bjh.12545
Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transpl. 2014;20:375–81.
doi: 10.1016/j.bbmt.2013.11.033
Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2014;20:1580–5.
doi: 10.1016/j.bbmt.2014.06.015
Erbey F, Atay D, Akcay A, Ovali E, Ozturk G. Mesenchymal stem cell treatment for steroid refractory graft-versus-host disease in children: a pilot and first study from Turkey. Stem Cells Int. 2016;2016:1641402.
pubmed: 26783400
doi: 10.1155/2016/1641402
Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2017;52:859–62.
doi: 10.1038/bmt.2017.35
Ringden O, Baygan A, Remberger M, Gustafsson B, Winiarski J, Khoein B, et al. Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. Stem Cells Transl Med. 2018;7:325–31.
pubmed: 29533533
pmcid: 5866941
doi: 10.1002/sctm.17-0167
Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, et al. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. Br J Haematol. 2019;185:89–92.
pubmed: 30637732
pmcid: 6916615
doi: 10.1111/bjh.15749
van der Wagen LE, Miranda-Bedate A, Janssen A, Fernando F, Appukudige N, van Dooremalen S, et al. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile. Bone Marrow Transpl. 2020;55:2188–92.
doi: 10.1038/s41409-020-0910-9
Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3:225–38.
pubmed: 23997985
pmcid: 3755522
von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells. 2016;34:357–66.
doi: 10.1002/stem.2224
Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transpl. 2017;52:606–8.
doi: 10.1038/bmt.2016.317
Kuçi Z, Bönig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, et al. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica.2016;101:985–94.
pubmed: 27175026
pmcid: 4967578
doi: 10.3324/haematol.2015.140368
Bader P, Kuçi Z, Bakhtiar S, Basu O, Bug G, Dennis M, et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transpl. 2018;53:852–62.
doi: 10.1038/s41409-018-0102-z
Bonig H, Kuçi Z, Kuçi S, Bakhtiar S, Basu O, Bug G, et al. Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”-outcome report of 92 patients. Cells .2019;8:1577.
pmcid: 6952775
doi: 10.3390/cells8121577
pubmed: 6952775
Rizk M, Monaghan M, Shorr R, Kekre N, Bredeson CN, Allan DS. Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence. Biol Blood Marrow Transpl. 2016;22:1416–23.
doi: 10.1016/j.bbmt.2016.04.010
Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, et al. A phase 3 randomized study of remestemcel-l versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26:835–44.
doi: 10.1016/j.bbmt.2019.08.029
Kurtzberg J, Prockop S, Chaudhury S, Horn B, Nemecek E, Prasad V, et al. Study 275: updated expanded access program for remestemcel-l in steroid-refractory acute graft-versus-host disease in children. Biol Blood Marrow Transpl. 2020;26:855–64.
doi: 10.1016/j.bbmt.2020.01.026
Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al. A phase 3, single-arm, prospective study of remestemcel-l, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26:845–54.
doi: 10.1016/j.bbmt.2020.01.018
Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98:206–13.
pubmed: 23860964
doi: 10.1007/s12185-013-1399-4
Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103:243–50.
pubmed: 26608364
doi: 10.1007/s12185-015-1915-9
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.
pubmed: 17988995
doi: 10.1007/BF03006932
Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.
pubmed: 26547570
doi: 10.1007/s12185-015-1894-x
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J. et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.
doi: 10.1016/j.bbmt.2005.09.004
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
doi: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972;34:187–220.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N. Engl J Med 2020;382:1800–10.
pubmed: 32320566
doi: 10.1056/NEJMoa1917635
Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist .2020;25:e328–4.
pubmed: 32043777
doi: 10.1634/theoncologist.2019-0627
Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood .2017;129:643–9.
pubmed: 27899357
doi: 10.1182/blood-2016-09-738625
Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18:1150–63.
doi: 10.1016/j.bbmt.2012.04.005
García-Cadenas I, Rivera I, Martino R, Esquirol A, Barba P, Novelli S, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transpl. 2017;52:107–13.
doi: 10.1038/bmt.2016.225
Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transpl. 2009;15:777–84.
doi: 10.1016/j.bbmt.2009.03.012
Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:804–11.
doi: 10.1016/j.bbmt.2008.03.012
Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, et al. Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT. Bone Marrow Transpl. 2017;52:252–7.
doi: 10.1038/bmt.2016.247
Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood .2004;104:649–54.
pubmed: 15069017
doi: 10.1182/blood-2003-12-4241
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood .2014;123:3664–71.
pubmed: 4047501
pmcid: 4047501
doi: 10.1182/blood-2014-01-552984
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367–9.
doi: 10.1016/j.bbmt.2008.12.497